Ni · Aging cell 2026 · in vitro and ex vivo mechanistic laboratory study · n=?

Senescence-Driven IL-17A Inflammatory Circuit Promotes Epithelial-Mesenchymal Transition (EMT) and Progression in Age-Related Posterior Subcapsular Cataracts.

Cited 0 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Laboratory and bench translational research using human ex vivo tissue, aqueous humor profiling, and in vitro cellular assays

PubMed 41876404 · doi:10.1111/acel.70456 · record verified 2026-08-29

What was done

The authors examined human lens samples from patients with age-related posterior subcapsular cataracts (ARC-PSC), age-related nuclear cataracts (ANC), and clear lenses to assess epithelial-mesenchymal transition (EMT) marker expression. They performed transcriptomic profiling of lens epithelial cells (LECs) and characterized cytokine profiles in aqueous humor across PSC subtypes. In vitro functional experiments were conducted using senolytic agents and IL-17A blockade to evaluate their effects on senescence and EMT-associated cellular phenotypes.

What was found

The abstract reports no numerical values, sample sizes, or statistical metrics. Qualitatively, transcriptomic analyses revealed elevated EMT signatures linked to senescence-associated inflammatory signaling in ARC-PSC LECs compared to ANC and clear lenses. Aqueous humor profiling demonstrated elevated pro-inflammatory signaling across PSC subtypes, with IL-17A uniquely increased in ARC-PSC. In vitro, senolysis and IL-17A inhibition disrupted NF-κB-mediated signaling and reduced senescence- and EMT-associated phenotypes.

Why it matters

This study provides a cellular and inflammatory explanation for the development of posterior subcapsular cataracts beyond standard crystallin aggregation models. Identifying the IL-17A-NF-κB axis highlights potential non-surgical targets, such as senolytics or cytokine inhibitors, for preventing PSC progression.

Limits

The abstract provides no sample sizes (n) for human lens or aqueous humor specimens, nor does it report quantitative effect sizes or confidence intervals. Findings regarding pathway intervention rely solely on in vitro models, lacking in vivo animal or human clinical efficacy and safety validation.

Cited by